Letter by Koh Regarding Article, “Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Steg and Roussel1 discussed problems of the cardiovascular safety trials of antihyperglycemic agents implemented by the US Food and Drug Administration and European Medicines Agency guidance. They raised 3 issues: (1) extent to which the trials are relevant to the population concerned, (2) cost, and (3) perception. They cautiously hypothesized that, ironically, the cardiovascular benefits observed in some recent trials might be at least partially explained by the reduction in hyperglycemia.
To be frank, physicians are now in chaos. Palmer et al2 reported on a meta-analysis of 301 clinical trials, which showed no significant differences in the associations among any …